Physician profile
David Glassman
NPI 1831127265
$2,860.43
in general payments reported to CMS, 2019-2025
13 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $303 · 2021: $270 · 2022: $702 · 2023: $267 · 2024: $185 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $805 · Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $804.84 |
| Food and Beverage | $473.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $804.84 | 2025 | Excelsius Gps |
| Medtronic, INC. | $557.74 | 2021-2023 | Intellis Adaptivestim |
| Medtronic USA, INC. | $463.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $375.36 | 2019-2024 | Bridion |
| Vertos Medical, INC. | $184.99 | 2023-2024 | Mild Device Kit |
| Bioventus LLC | $175.53 | 2019-2022 | |
| Abbvie INC. | $151.17 | 2022-2023 | |
| Stryker Corporation | $45.61 | 2021 | |
| Allergan, INC. | $25.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.31 | 2025 | |
| Heron Therapeutics, INC. | $21.29 | 2024 | Aponvie |
| Endo Pharmaceuticals INC. | $19.34 | 2019 | |
| Horizon Therapeutics Plc | $12.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Glassman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.